• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Recent Advances in the Study of 2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide (CAS: 175137-34-5)

2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide (CAS: 175137-34-5) is a pyrazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of antimicrobial, anti-inflammatory, and anticancer agents. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential applications in drug discovery.

The compound's unique structure, featuring a chlorophenyl group and a trifluoromethyl group on the pyrazole ring, contributes to its diverse reactivity and biological activity. Recent synthetic methodologies have focused on optimizing the yield and purity of 2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide, with studies reporting improved catalytic processes and greener synthetic routes. These advancements are critical for scaling up production and ensuring the compound's availability for further pharmacological evaluation.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated that 2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide exhibits promising antimicrobial properties against a range of Gram-positive and Gram-negative bacteria. Mechanistic studies suggest that the compound disrupts bacterial cell wall synthesis, making it a potential candidate for addressing antibiotic resistance. Additionally, its anti-inflammatory effects have been linked to the inhibition of key pro-inflammatory cytokines, such as TNF-α and IL-6, which are implicated in chronic inflammatory diseases.

Another area of interest is the compound's potential anticancer activity. Preliminary studies have shown that it can induce apoptosis in certain cancer cell lines, particularly those associated with breast and lung cancers. Researchers are investigating its mechanism of action, with a focus on its ability to modulate signaling pathways involved in cell proliferation and survival. These findings underscore the compound's versatility and its potential as a scaffold for developing targeted therapies.

Despite these promising results, challenges remain in translating these findings into clinical applications. Issues such as bioavailability, toxicity, and metabolic stability need to be addressed through further preclinical studies. Recent efforts have also explored the derivatization of 2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide to enhance its pharmacological profile, with some derivatives showing improved efficacy and reduced side effects in animal models.

In conclusion, 2-(4-Chlorophenyl)-3-(Trifluoromethyl)Pyrazole-4-Carboxylic Acid Hydrazide (CAS: 175137-34-5) represents a promising compound in the field of medicinal chemistry, with diverse biological activities and potential therapeutic applications. Ongoing research aims to optimize its synthesis, elucidate its mechanisms of action, and develop derivatives with enhanced properties. These efforts could pave the way for its eventual use in treating various diseases, contributing to the advancement of chemical biology and drug discovery.

• 175137-32-3(1-Phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carbohydrazide)
• 125048-87-5(1H-Pyrazole-4-carboxamide,1-(4-chlorophenyl)-5-(trifluoromethyl)-)
• 1185292-87-8(1-Phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide)
• 618091-00-2(1-(2-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbohydrazide)
• 618092-42-5(1-(4-Chlorophenyl)-5-methyl-1H-pyrazole-4-carbohydrazide)
• 98534-22-6(1H-Pyrazole-4-carboxamide,1-(2,4-dichlorophenyl)-N-methyl-5-(trifluoromethyl)-)
• 98534-80-6(1-(4-Chlorophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic Acid)
• 98534-26-0(1H-Pyrazole-4-carboxamide,1-(4-chlorophenyl)-N-cyclopropyl-5-(trifluoromethyl)-)
• 102996-38-3(1H-Pyrazole-4-carboxamide,1-(2,4-dichlorophenyl)-5-(trifluoromethyl)-)
• 618090-91-8(1-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbohydrazide)